

Research article

Open Access

Intracellular amyloid formation in muscle cells of A β -transgenic *Caenorhabditis elegans*: determinants and physiological role in copper detoxification

Alicia N Minniti¹, Daniela L Rebolledo¹, Paula M Grez¹, Ricardo Fadic², Rebeca Aldunate¹, Irene Volitakis³, Robert A Cherny³, Carlos Opazo⁴, Colin Masters³, Ashley I Bush^{3,5} and Nivaldo C Inestrosa*¹

Address: ¹Centro de Regulación Celular y Patología "Joaquín V. Luco" (CRCP), MIFAB, Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Alameda 340, 8331010 Santiago, Chile, ²Departamento de Neurología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, ³Oxidation Disorders Laboratory, Mental Health Research Institute of Victoria and Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia, ⁴Laboratorio de Neurobiometales, Departamento de Fisiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Chile and ⁵Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Charlestown, Massachusetts, USA

Email: Alicia N Minniti - aminniti@bio.puc.cl; Daniela L Rebolledo - dvrebol@puc.cl; Paula M Grez - pgrez@indiana.edu; Ricardo Fadic - rfadic@med.puc.cl; Rebeca Aldunate - raldunate@bio.puc.cl; Irene Volitakis - ivolitakis@mhri.edu.au; Robert A Cherny - rcherny@mhri.edu.au; Carlos Opazo - carlosopazo@udec.cl; Colin Masters - c.masters@unimelb.edu.au; Ashley I Bush - bush@helix.mgh.harvard.edu; Nivaldo C Inestrosa* - ninestrosa@bio.puc.cl

* Corresponding author

Published: 6 January 2009

Received: 4 September 2008

Molecular Neurodegeneration 2009, 4:2 doi:10.1186/1750-1326-4-2

Accepted: 6 January 2009

This article is available from: <http://www.molecularneurodegeneration.com/content/4/1/2>

© 2009 Minniti et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The amyloid β -peptide is a ubiquitous peptide, which is prone to aggregate forming soluble toxic oligomers and insoluble less-toxic aggregates. The intrinsic and external/environmental factors that determine A β aggregation *in vivo* are poorly understood, as well as the cellular meaning of this process itself. Genetic data as well as cell biological and biochemical evidence strongly support the hypothesis that A β is a major player in the onset and development of Alzheimer's disease. In addition, it is also known that A β is involved in Inclusion Body Myositis, a common myopathy of the elderly in which the peptide accumulates intracellularly.

Results: In the present work, we found that intracellular A β aggregation in muscle cells of *Caenorhabditis elegans* overexpressing A β peptide is affected by two single amino acid substitutions, E22G (Arctic) and V18A (NIC). Both variations show decrease intracellular amyloidogenesis compared to wild type A β . We show that intracellular amyloid aggregation of wild type A β is accelerated by Cu²⁺ and diminished by copper chelators. Moreover, we demonstrate through toxicity and behavioral assays that A β -transgenic worms display a higher tolerance to Cu²⁺ toxic effects and that this resistance may be linked to the formation of amyloid aggregates.

Conclusion: Our data show that intracellular A β amyloid aggregates may trap excess of free Cu²⁺ buffering its cytotoxic effects and that accelerated intracellular A β aggregation may be part of a cell protective mechanism.

Background

Aberrant protein aggregation is a common feature of late-onset amyloidogenic diseases, such as Alzheimer's disease (AD) and Inclusion Body Myositis (IBM) [1]. A peptide of 39–43 mer derived from the amyloid precursor protein (APP), the amyloid β -peptide ($A\beta$), is the main constituent of senile plaques (SPs) in AD [2], and it is also one of the hallmarks of IBM, a common myopathy characterized by the presence of intracellular amyloid aggregates in skeletal muscle cells [1,3]. IBM patients show progressive muscle weakness, compromised muscle innervation [4] and muscle fibre degeneration [5]. Besides the presence of senile plaque-like inclusions, most molecules known to be involved in IBM are also present in AD [6].

Dominant mutations in the APP gene are associated with rare cases of familial AD, in which brain and vascular amyloid deposits are formed earlier than in sporadic cases [7]. One type of familial AD is linked to a point mutation in the $A\beta$ peptide (E22G, Arctic) that accelerates aggregation of $A\beta$ into protofibrils and fibrils *in vitro* [8-12]. Some transgenic mice carrying the Arctic mutation show increased plaque formation but normal learning and memory compared to strains carrying the wild type $A\beta$ [13]. Opposite to the Arctic variant, *in vitro* studies demonstrated that the NIC mutation (V18A), which is predicted to favour the α helix conformation over the β sheet conformation, shows decreased aggregation [14].

Although APP and $A\beta$ have been implicated in several processes *in vitro* and *in vivo*, such as neuronal development and cell survival, the *in vivo* functions of APP and $A\beta$ remain unclear [7,15,16]. Moreover, the inactivation of the complete APP gene family has shown that APP is necessary for neurodevelopment and cell adhesion [17]. In addition, neither the *in vivo* mechanisms of amyloid formation nor the factors required for this process have been properly established. It is also unknown if the formation of insoluble amyloid aggregates is instrumental for the onset of these amyloidogenic diseases, or if the formation of amyloid structures is the end product of the cell protective machinery. SPs are structured as metal-enriched aggregates that accumulate Cu^{2+} , Fe^{3+} , and Zn^{2+} [18-20]. In agreement with this, the aggregation state of $A\beta$ -peptide is increased by Cu^{2+} or Zn^{2+} [21] and reduced by metal chelators such as clioquinol [22-24]. However, the role of copper as deleterious or beneficial in the context of amyloidogenic diseases is very controversial. For instance, in a transgenic APP23 mouse model, supplementation of the diet with bioavailable copper restored normal levels of SOD-1 activity and decreased the production of soluble $A\beta$ [25]. From these studies, the structural plasticity of the SP is becoming evident in agreement with previous structural data [26]. In light of this evidence we postulate that the formation of the SP might be triggered by fluctuations

on the levels of transition metals, and could be a part of a protective homeostatic mechanism gone off-course. However, it is unknown if these metals are accumulated in the intracellular amyloid aggregates observed in IBM and if the aggregation state of $A\beta$ is modulated by transition metals in this intracellular muscle environment. Interestingly, IBM patients do not develop dementia and AD patients do not have the muscle weakness characteristic of IBM, which indicates that these diseases may be triggered by independent mechanisms [1].

Caenorhabditis elegans has an APP homologue but this protein lacks a region equivalent to the $A\beta$ -peptide [27]. However, several studies carried out in $A\beta$ overexpressing *C. elegans* [6] have established that the formation of amyloid deposits [28] could induce oxidative stress [29], stress response [30,31] and up- or down-regulation of different genes [32]. However, the toxic $A\beta$ -species responsible for these effects detected in $A\beta$ -transgenic worms have not been thoroughly identified, but they are likely to be a specific type of $A\beta$ oligomers rather than mature $A\beta$ amyloid aggregates [33-35]. It is important to mention that the paralysis phenotype is only observed in $A\beta$ expressing *C. elegans* in a dominant *rol-6* background (strains carrying a mutation in a collagen gene) [32]. In fact, the great majority of IBM patients show muscle weakness that translates in a lower quality of life but not paralysis or decreased longevity [36].

In the present work, we evaluated intrinsic and extrinsic factors on the aggregation of intracellular $A\beta$ peptides constitutively overexpressed in muscle cells of *C. elegans*. Our results indicate that intracellular $A\beta$ aggregation is selectively affected by single amino acid substitution, which is in agreement with previously published *in vitro* data [14]. Under our experimental conditions, we find that the NIC mutation (V18A) did form fewer Thioflavine-S (ThS)-positive aggregates compared to $A\beta$ wt. Neither non-aggregating $A\beta$ peptide nor aggregating $A\beta$ peptide induced strong paralysis phenotypes in these animals in a wild type background. However, $A\beta$ wild type affected the worms' motility as they aged mimicking the muscle weakness observed in IBM patients. Therefore, we asked the question whether $CuCl_2$ could modulate the aggregation of intracellular $A\beta$ -peptide in muscle cells, as it is apparent with the extracellular $A\beta$ -peptide in transgenic vertebrate models for AD [22,37]. We found that Cu^{2+} increases the number of intracellular ThS-positive aggregates present in this model. In contrast, the presence of the Cu-chelators histidine and clioquinol in the growing medium decreases the formation of amyloid deposits. Surprisingly, the $A\beta$ -expressing animals, in spite of producing a great number of amyloid aggregates in the presence of Cu^{2+} , exhibited increased tolerance to the cytotoxic effects of $CuCl_2$ compared to control animals.

Therefore, the present evidence suggests, for the first time, that intracellular amyloid deposits are dynamically structured by the presence of metals in muscle cells, and that the formation of intracellular A β aggregates could be a part of the homeostatic mechanism responsible for protecting cells against abrupt changes in Cu²⁺ levels.

Results

The NIC A β_{1-42} variant displays a low rate formation of intracellular amyloid deposits in *C. elegans* muscle cells

In order to investigate the key intrinsic determinants of the human A β sequence for A β intracellular amyloid aggregation, we constructed transgenic *C. elegans* strains that express two different variants, Arctic (E22G) and NIC (V18A) (Fig. 1A, B, C and 1D), in muscle cells as described in the Methods section. Interestingly, despite having generated several transgenic lines that expressed the Arctic variant, all of them showed levels of expression far lower than those expressing the wild type or the NIC variant (Fig. 1C and 1D). One possibility is that the overexpression of the Arctic variant in *C. elegans* muscle cells is too harmful and therefore the only surviving transgenic lines were those with low A β Arctic expression. For our experiments we used the strain NIC2, with A β load similar to that of the A β wt expressing strain, and Arctic 6.

We then analyzed the degree of amyloidosis at different times during the animal's life to establish the pattern of intracellular aggregation. Fig. 2(A, B) shows the time course of amyloid formation as visualized by ThS staining. The animals were processed and stained at 48, 72, 96 and 120 h after being synchronized at the embryo stage. All transgenic strains show an increment in the total amyloid deposit area as they age (Fig. 2B). However, the animals expressing the A β variants show fewer amyloid aggregates than those that express the A β wt at all ages. The worms expressing the NIC variant start showing amyloid deposits by 48 h but to a lesser extent than those expressing the A β wt. Over the next time points (up to 120 h) the formation of amyloid deposits increased in these animals, but to a much lesser extent than in those expressing the A β wt (Fig. 2A, B) as anticipated from previous *in vitro* experiments [14]. We were not able to detect any ThS positive spots until 72 h in the animals that express the Arctic variant, which suggests a delay in the formation of mature amyloid deposits as expected. However, in the next time points, the degree of amyloid formation in these transgenic animals was very poor, even lower than those expressing the NIC variant (Fig. 2A, B). We expect this low level of amyloid formation of the Arctic variant is due to the poor expression of the transgene compared with the strains carrying the wild type and NIC variants (Fig. 1C, D). Fig. 3 shows the expression of the three A β variants in the transgenic *C. elegans* lines by immunofluorescence (120 h). They all show expression of the A β peptide

(green) in the muscle cells identified by phalloidin staining of actin filaments (red). As shown in the orthogonal analyses (Fig. 3B, D, F) the A β concentrated in aggregates is mainly located between the actin filaments, which are well observed in *C. elegans* overexpressing the A β wt variant (Fig. 3A, B). Even though the Arctic variant formed very few and small amyloid deposits (probably as a consequence of low expression of the transgene (Fig. 1D)), the peptide accumulates in what appears to be fairly big amorphous aggregates, which were A β -immunoreactive (Fig. 3C, D). We do not observe clear muscle degeneration in any of the transgenic strains since actin fibers look fairly intact (Fig. 3).


Cu²⁺ modulates intracellular A β amyloidosis in transgenic *C. elegans*

To evaluate if the aggregation state of A β expressed in the muscle cells of the worms could be altered by environmental factors, we decided to expose the worms to copper, mainly because there is a large body of evidence indicating that the aggregation of A β in the brain can be modulated by transition metals [25,38,39]. We performed experiments with copper using the strain expressing the human wild type A β peptide, since it is the most commonly found in amyloidogenic diseases, the best characterized, and it behaves as expected in our previous studies. We first analyzed the formation of amyloid aggregates by staining synchronized populations of animals cultured on Cu²⁺, histidine and cloiquinol supplemented medium every 24 h. Time zero was established as the time the eggs were harvested and seeded onto agar plates supplemented with the CuCl₂, histidine or cloiquinol. The CuCl₂ concentrations used in the experiments were determined by preliminary studies of viability, fertility and Cu²⁺ incorporation in the wild type (N2) strain and analysis of stress induction in the *hsp-16::GFP* transgenic strain CL2070 [31,40]. Based on these studies we decided to use a concentration of 150 μ M CuCl₂, because it did not affect the survival of the worms. Cu-chelators were also used at a concentration of 150 μ M. As previously reported, ThS reactive deposits were not observed in very young animals although their presence has been established even in embryos by staining with the more sensitive Congo-red derived dye X-34 [41]. We started seeing ThS positive deposits 48 h after the eggs were seeded on the plates, when most of the animals were L4 larvae (data not shown). Before this time, it was not possible to perform a quantitative analysis between the different treatments. The number of ThS positive deposits was quantified anterior to the pharyngeal bulb in the cephalic region of the worms (Fig. 4A), as described in the Methods section. Up to 72 h of treatment, the differences in the number of amyloid deposits between the animals exposed to CuCl₂, histidine or cloiquinol did not appear significantly different from controls (Fig 4C). After 96 h of treatment, the


A

Aβ wt DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Aβ Arctic DAEFRHDSGYEVHHQKLVFFAGDVGSNKGAIIGLMVGGVVIA
Aβ NIC DAEFRHDSGYEVHHQKLAFFAGDVGSNKGAIIGLMVGGVVIA

B



C



D




Figure 1 (see legend on next page)

Figure 1 (see previous page)

Transgenic *C. elegans* strains express the A β wild type and its variants Arctic and NIC. A. Amino acidic sequences of the A β ₁₋₄₂ peptide (wild type) and its variants Arctic and NIC expressed in the transgenic *C. elegans* strains used in this study. **B.** PCR results show the presence of the DNAs that encode the different peptides in the transgenic strains. CL2120 is the strain that express A β wt and CL2122 is the control strain that do not express the peptide. NIC corresponds to transgenic line NIC2 and Arctic corresponds to transgenic line Arctic 6. *unc-119* is the strain used to construct the transgenic lines carrying the NIC and Arctic variants. **C.** Western blot analysis using the anti-A β antibody 6E10 showing the expression of A β in the CL2120 (wild type A β) strain and in two NIC transgenic lines (NIC 1 and NIC 2). The lane marked as "no A β " correspond to strain CL2122. **D.** Western blot analysis using the same antibody as in C showing the expression of A β in strain CL2120 (wild type A β) and in four Arctic transgenic lines (Arctic 13, Arctic 6, Arctic 37, Arctic 5D). The lane marked as "no A β " correspond to strain CL2122. α -Tubulin was used as loading control in C and D.

formation of ThS-positive deposit was more abundant in the worms grown in CuCl₂ than in the worms cultured in the control medium (Fig 4B a–b, C). At this time, the worms cultured in the agar supplemented with Cu-chelators developed scarce amyloid deposits, significantly less than the number of deposits formed in the worms grown in the control medium (Fig. 4B a–d; C). The same pattern was observed at 144 h of treatment (Fig. 4C). We confirmed this quantification by measuring the total aggregate area in the worm's cephalic region at 96, 120 and 144 h (Fig. 4D). As expected, the CuCl₂ treatment increased the total deposit area, while histidine and clioquinol reduced it significantly. Moreover, at this time, the few aggregates formed in the presence of histidine and clioquinol seemed to have a more diffuse morphology than the ThS-amyloid aggregates formed in the presence of CuCl₂ and controls (Fig. 4Bc and 4d). In addition, the treatment with clioquinol often produced a virtual absence of discernible aggregates (Fig 4Bd).


Cu²⁺ tolerance in A β - transgenic *C. elegans*

A β has a strong affinity for Cu²⁺ [42], therefore, we set up to test whether there was a differential tolerance to the toxic effects of CuCl₂ between the A β expressing worms (CL2120) and the controls (CL2122). We reasoned that if Cu²⁺ becomes bound to A β , there would be less free Cu²⁺ to cause cell damage. To test this hypothesis we performed toxicity assays in which we exposed 96 h old A β -expressing worms and their controls to a range of copper concentrations ranging from zero (no copper added to the medium) to 450 μ M in liquid medium during 24 h. In this way we were able to define survival curves for both populations and found a significant shift to the right for the A β transgenic animals (Fig. 5A). The lethal concentration at which half of the population dies (LC₅₀) was significantly higher for the animals expressing the A β peptide (366 \pm 2 μ M) than the controls (268 \pm 8 μ M). These results show that the A β transgenic worms are more resistant than controls to high Cu²⁺ concentrations suggesting that there might be less metal available to produce cell damage in this strain. We confirmed that the animals exposed to high concentrations of CuCl₂ (150 μ M) during


96 and 120 h incorporated more Cu²⁺ (\approx 10 μ g/g) than the animals grown on regular medium (\approx 0.1 μ g/g) (Table 1). Moreover, Cu²⁺ supplementation did not induce changes in Zn²⁺, Fe³⁺, Mn²⁺ or Al³⁺ levels (data not shown). We did not observe any significant difference in constitutive Cu (or Zn²⁺, Fe³⁺, Mn²⁺ and Al³⁺) levels between the A β -transgenic *C. elegans* and their controls, indicating that the presence of A β does not affect Cu²⁺ absorption from the agar medium. Therefore, the aggregation of intracellular A β was mediated by direct reaction with elevated Cu²⁺. In fact, the A β -transgenic animals and their control counterparts exposed to CuCl₂, incorporated about 100 times more Cu²⁺ than the animals grown under normal culture conditions. However, we did not observe any statistically significant difference in the amount of incorporated Cu²⁺ between the A β -transgenic *C. elegans* and their controls under either condition (no CuCl₂ added and CuCl₂ supplementation) (Table 1), indicating that the presence of A β is not affecting Cu²⁺ transport, and suggesting that the effect observed on the experiments could be explained principally by the interaction between Cu²⁺ and the A β present in the muscle cells of the nematode. These results show that the A β transgenic worms are more resistant than controls to high Cu²⁺ concentrations.

In order to confirm that the protective effect of A β expression is limited to copper toxicity we performed CdCl₂ and ZnCl₂ toxicity assays. Both metals are known to be toxic and to elicit a stress response in *C. elegans* [43-45]. Furthermore, zinc is known to be involved in the metallobiology of Alzheimer's disease [46]. We found that the survival curves (Fig. 5C, D) are almost identical between A β expressing worms and controls in both cases. The differences in LC₅₀ for cadmium (CL2120: 1.55 \pm 0.02 mM; CL2122: 1.59 \pm 0.03 mM) and zinc (CL2120: 4.9 \pm 0.8 mM; CL2122: 4.8 \pm 0.4 mM) are not statistically significant between the strains. These results exclude the possibility that A β overexpression may be providing a more general protective effect, at least to metal toxicity.

Finally, to correlate amyloid aggregate load with resistance to copper toxicity, we performed lifespan experi-

**Figure 2**

Amyloid formation in transgenic *C. elegans* expressing different $A\beta$ variants. **A.** Images show ThS stained *C. elegans* that express the $A\beta_{1-42}$ wt or its variants Arctic and NIC. The visualization of the amyloid deposits (arrow heads) in these strains is shown at 48 h (larval stage L4), 72 h (1 day old adult), 96 h (2 day old adult) and 120 h (3 day old adult) of development. The images are representative of 4 experiments where 40 worms were analyzed for each time point. Bar 20 μ m. **B.** Quantification of amyloid deposit area in ThS stained transgenic *C. elegans* expressing the $A\beta$ variants mentioned above. The quantification of the amyloid deposit area was also done at 48, 72, 96 and 120 h of development in the head of at least 40 worms for each time point, from the tip of the head to the end of the pharynx (see Fig. 4A).

**Figure 3**

Transgenic *C. elegans* strain expressing the Arctic A β peptide shows high levels of non-amyloidogenic aggregates. Panels **A**, **C** and **E** show confocal images of 120 h old worms that express the A β wt, the Arctic and the NIC variants, respectively, stained with anti-A β antibodies (green) and phalloidin (red) to show the actin filaments in body wall muscle cells. Panels **B** (A β wt), **D** (A β Arctic) and **F** (A β NIC) show the orthogonal view of the same animals shown in A, C and E, to establish the location of the A β aggregates in relation to the actin filaments. Bar 20 μ m.




Figure 4 (see legend on next page)

Figure 4 (see previous page)

Cu²⁺ and Cu-chelators modulate the aggregation state of intracellular A β wt in transgenic *C. elegans*. **A.** The white rectangle on the DIC image of a *C. elegans* hermaphrodite (top picture) indicates the region of the worm where all quantifications were done (the same region, stained with ThS in seen below). * Indicates the position of the pharyngeal bulb. **B.** Morphology of ThS-positive amyloid deposits formed in the presence of Cu²⁺ and Cu-chelators. Images correspond to *C. elegans* grown on regular NGM agar plates (a), treated with 150 μ M CuCl₂ (b), 150 μ M histidine (c) or 150 μ M clioquinol (d) for 144 h. The amyloid deposits were stained with ThS and photographed under an epifluorescence microscope. Arrows indicate ThS positive amyloid aggregates. The images are representative of 4 experiments where 40 worms were analyzed for each treatment. Bar 20 μ m. **C.** The graph represents the number of aggregates formed anterior to the pharyngeal bulb at different times (48–144 h) under control conditions (white bars) and when the animals were treated with CuCl₂ (150 μ M, black bars), histidine (150 μ M, dark grey bars), or clioquinol (150 μ M, pale gray bars). Bars indicate standard error, **p < 0.01; ***p < 0.001. **D.** The graph shows the digital quantification (Sigma Scan Pro 5) of the ThS-positive amyloid deposits present anterior to the pharyngeal bulb. The graph represents the total area of aggregates formed anterior to the pharyngeal bulb at different times (96–144 h) under control conditions (white bars) and when the animals were cultured in the presence of CuCl₂ (150 μ M, black bars), histidine (150 μ M, dark grey bars), or clioquinol (150 μ M, pale gray bars). Bars indicate standard error, *p < 0.05; **p < 0.01; ***p < 0.001. The p values indicate differences between a given treatment and the control.

ments to determine if A β expressing worms show longer lifespan than controls under 150 μ M copper. We found that A β worms show a small but significant increase in median and total lifespan (Fig. 5B) demonstrating the protective effect of A β when the worms were chronically exposed to copper. When cultured on regular agar, the A β expressing worms and the control animals show a similar lifespan (Additional file 1).

A β -transgenic *C. elegans* are protected from Cu²⁺ toxicity in behavioral assays

To further corroborate the protective effect of A β expression to copper toxicity we performed thrashing assays [47]. These assays measure motor deficits in liquid medium and have been used extensively in studies of mutants that affect the function and/or structure of the *C. elegans* neuromuscular junction [47-49]. We first evaluated the motility of A β expressing worms and controls

that had been cultured in regular agar plates for 72 and 120 h (from the embryo stage). We found that the transgenic A β animals move 40% slower than controls (Fig. 6), indicating that A β is indeed affecting the worms' behaviour, even though this is not evident when they crawl on agar plates. Then, we evaluated the motility of A β expressing animals and their controls after being cultured on agar medium supplemented with 150 μ M CuCl₂ during the same periods of time (72 and 168 h). We found that while the control animals show decreased movement at both time points after being cultured in copper rich agar plates, the A β expressing worms are not affected under the same conditions and they even show significant improvement (Fig. 6 and Additional files 2 and 3).


Discussion

Most of the studies performed to understand intracellular A β aggregation and amyloid formation have been done using *in vitro* systems. Therefore, neither the *in vivo* mechanisms of amyloid formation nor the factors required for this process have been established [15]. In the present work, we evaluated intrinsic and extrinsic factors in the aggregation of A β peptides constitutively overexpressed in muscle cells of *Caenorhabditis elegans*. Under our experimental conditions, we found that A β peptide carrying the Arctic (E22G) or the NIC mutation (V18A) did form few ThS-positive aggregates compared to A β wt. The results obtained with the NIC (V18A) variant are in agreement with previously published *in vitro* data [14]. This mutation is expected to favor the α helix over the β sheet conformation, which would cause a decrease in amyloidosis [14]. However, the results obtained with the Arctic mutation (E22G) are at variance with the literature [50]. The initial delay in the formation of aggregates is in agreement with the kinetics of aggregation of the Arctic variant *in vitro* in which there is a lag in the formation of amyloid in favor of the development of protofibrils, when compared with

Table 1: Copper incorporation into A β expressing *C. elegans* and controls

Age [h]	Strain	Cu ²⁺ Content [μ g/g protein]	
		No copper added	CuCl ₂ 150 μ M
96	No A β	0.350 \pm 0.458	8.831 \pm 1.077
	A β ₁₋₄₂	0.169 \pm 0.142	12.109 \pm 2.523
120	No A β	0.128 \pm 0.110	9.931 \pm 0.930
	A β ₁₋₄₂	0.068 \pm 0.015	9.224 \pm 1.989


Quantification of Cu²⁺ incorporated in control (CL2122 = no A β expression) and A β -transgenic (CL2120 = A β ₁₋₄₂) *C. elegans*. Worms were grown in the presence of CuCl₂ (150 μ M) or under control conditions (no copper added) for 96 and 120 h. The Cu²⁺ content (μ g/g) was determined by ICP-MS. Data are means \pm S.E.

**Figure 5**

C. elegans that express Aβ are resistant to Cu²⁺ toxicity. **A.** Control (open circles) and Aβ wt expressing animals (black circles) were exposed to a range of CuCl₂ (**A**), CdCl₂ (**C**), and ZnCl₂ (**D**) concentrations in liquid K medium for 24 h. The number of worms that remained alive was determined under a stereoscope by visual inspection. The experiments were performed in triplicate. Data are means ± S.E. **p < 0.01; ***p < 0.001. **B.** Survival curves of control worms and Aβ worms cultured on 150 μM CuCl₂. Comparison of survival curves using the Log-rank (Mantel-Cox) test yielded a p value of 0.0066 (n = 138).

the Aβwt [12]. However, the poor amyloidogenesis in later time points (even lower than the NIC variant) is probably due to low transgene expression since the Arctic variant is known to be highly amyloidogenic as established in studies of transgenic mice expressing this human variant in the nervous system [13,50]. Our inability to

produce transgenic lines that constitutively express high levels of Aβ Arctic could be related to the deleterious effect of high levels of this variant during embryonic stages that may have preclude us from obtaining such strains. On the other hand, the immunofluorescence experiments show that much of the Aβ Arctic is aggregated in what appears

**Figure 6**

Aβ-transgenic *C. elegans* are protected from Cu²⁺ toxicity in motility assays. The graph represents the results of the thrashing assays (movement in liquid medium) performed on control and Aβ expressing worms after being cultured on regular agar or in copper supplemented agar for 72 or 168 h starting at the embryo stage. Statistical analysis: t-test to compare control worms (grey bars) with Aβ expressing worms (white bars) cultured on regular agar plates (no Cu²⁺) during 72 and 168 h. *** p < 0.001. t-test to compare control worms cultured on copper supplemented agar with control worms cultured on regular agar during 72 and 168 h. # p < 0.005, ### p < 0.001; and to compare Aβ worms cultured on copper supplemented agar (150 μM) with Aβ worms cultured on regular agar during 72 and 168 h. # p < 0.005, ### p < 0.001. Bars indicate standard error. See representative videos in Additional files 2 and 3.

to be amorphous deposits. Perhaps, there are muscle expressed factors that prevent the formation of mature amyloid deposits of the Aβ Arctic variant.

In our model, Aβwt peptide expression induced a clear decrease in the worms' motility (Fig. 6), which could be compared to the progressive muscle weakness present in IBM patients. The lack of muscle degeneration observed in the Aβwt expressing animals suggests that the Aβ peptide might not be sufficient to induce a stronger myopathy by itself in the muscle cells of worms, and that extra factors might be needed to fully replicate IBM symptoms in *C. elegans*. The situation could be very similar to that seen in triple transgenic mice models for AD, where mice need to overexpress Aβ together with Tau and presenilin (all

mutant variants) to replicate the brain human features characteristic of the pathology [51]. Therefore, Aβ apparently needs to act with other factor/s present in the muscle to fully induce IBM symptoms in worm muscle [1].

We also showed that Cu²⁺ and the Cu²⁺ chelators histidine and clioquinol can modulate the formation of intracellular amyloid aggregates in *C. elegans* muscle cells. Copper ionophores like clioquinol and PBT2 show benefits in transgenic mouse models and phase 2 clinical trials of AD [22,24,52]. Despite the differences in cellular location, intracellular Aβ aggregation in *C. elegans* seems to be enhanced by Cu²⁺ and diminished by histidine and clioquinol in accordance with previous *in vitro* and *in vivo* reports [22,23]. The increased amyloidosis could also be

the result of higher A β expression brought about by Cu exposure and lower A β expression caused by Cu-chelator treatment. This situation is not likely to be the case because the constitutive *unc-54* promoter is driving A β expression. Moreover, it has been shown that in addition to aggregated A β -peptide there is an important pool of soluble peptide in worms expressing A β [30]. Therefore, increased peptide synthesis is not necessary for an eventual increment in A β for interaction and subsequent aggregation in the presence of Cu²⁺. We did, however, evaluate A β expression in worms subjected to the different treatments by semi-quantitative RT-PCR and found that there were no significant differences in its expression (data not shown). Therefore, these results support a pivotal role of Cu²⁺ in the aggregation state of intracellular A β .

In the present study, the animals were treated continuously with CuCl₂, histidine or clioquinol since they were embryos; at this stage there is no A β aggregation that can be observed by ThS staining although some aggregates have been detected with the X-34 dye [41]. Therefore, we have yet to establish whether treating animals with histidine or clioquinol later in life, once a significant number of deposits have been formed, can eliminate or reduce the number and/or size of the aggregates. Although we have shown an effect of Cu²⁺, histidine and clioquinol on the formation of intracellular amyloid deposits in muscle cells by histochemical staining with ThS, we have not yet resolved the question of the relative concentrations of soluble versus insoluble aggregated A β and their changes upon treatment with Cu-chelators. It would be very informative to clarify this point by double staining with ThS or X-34 to visualize the deposits, and A β antibodies that recognize both soluble and insoluble forms of the amyloid peptide. This experiment would clarify whether Cu²⁺ and Cu-chelators influence the equilibrium between both A β forms.

The differences observed among individuals exposed to the same treatments could be due to the developmental stage at which the animals start their exposure to the different agents. Even though we start the treatments on embryos, there is some difference in the actual developmental stage of the embryo (data not shown). Although this is a possibility, we do not think it is the case, since we have observed similar differences in animals cultured on standard medium. It is unlikely that the differences observed between same age individuals are due to genetic background. Self-fertilizing reproduction in *C. elegans* precludes much genetic variation in the strains. The strains used in our studies are transgenic strains in which several copies of A β had been integrated into the genome. However, integration of a transgene into the genome does not

always prevent mosaicism and/or differences in expression between individuals [53].

Another caveat is that we do not know if there is enrichment of metals (Cu, Zn and others) in the intracellular amyloid deposits of *C. elegans* muscle cells as is the case in the extracellular amyloid aggregates found in AD affected neuronal tissue [20]. The determination of metal levels in the muscle aggregates would be an important step in drawing a firmer analogy between AD extracellular brain aggregates and intracellular muscle deposits.

Perhaps the most striking finding is that the A β -expressing animals, in spite of producing great number of amyloid aggregates in the presence of Cu²⁺, exhibited increased tolerance to the cytotoxic effects of CuCl₂ compared to control animals and suggests that there might be less metal available to produce cell damage in this strain. The results from the behavioural experiments together with the results obtained in the toxicity assays offer strong evidence that A β may be providing protection to Cu²⁺ toxicity. Interestingly, the A β expressing worms that were exposed to CuCl₂ move better than those that were not cultured in the presence of this transition metal, suggesting that perhaps the increase in amyloid deposits in these treated worms is limiting the amount of the more toxic oligomeric species [33-35]. Our findings connect with those of other authors showing that increased A β deposition associates with decrease levels of neuronal oxidative damage in Down Syndrome and AD [54-57]. It has also been suggested that the chelation of redox-active copper and iron may be the most important mechanism by which A β exerts its protective function [58], and that at moderate copper concentrations, A β acts as an antioxidant to prevent Cu²⁺ catalyzed oxidation of biomolecules [59]. The levels of intracellular copper must be strictly regulated to prevent aberrant reactive oxygen species generation resulting in neuronal and muscle damage. In fact, intracellular free copper has been estimated to be almost nil [60], and is under the control of a robust metalloprotein array that rapidly and efficiently buffers free copper bioavailability. However, this protein array is clearly altered in age-related diseases such as Alzheimer's disease [61], which may explain why copper is accumulated in amyloid plaques of people suffering of this disease [20]. Moreover, a more recent report described that total brain copper levels increase in aged mouse [62]. Considering that age is a risk factor for AD neuropathology, brain copper rise in elderly humans may be one of the neurochemical factors relevant in the onset of AD. Moreover, cellular acidosis could facilitate the release of copper from metal binding proteins [63]. Interestingly, brain acidosis is observed in AD [64], which may facilitate the release of copper from copper-binding proteins increasing the formation of A β -Cu aggre-

gates. This may be also part of the mechanism that increases copper bioavailability in IBM.

Therefore, the present evidence suggests that intracellular amyloid deposits are dynamically structured by metals, and that A β may be a component of the system that specifically controls copper homeostasis at the cellular level [65-67].

Much research has been done on the possible role of copper and other metals such as zinc and iron on the development of AD, but so far no consensus has been reached in terms of the specific involvement of copper in this pathology, and conflicting reports point either to a deleterious role of copper [68] or a beneficial one [25]. Moreover, there is practically no data available about the possible role of metal homeostasis on other disorders characterized by amyloidosis such as sporadic IBM.

Conclusion

In this study we show in a *C. elegans* model that the intracellular senile plaque-like structures formed in muscle cells and characteristic of IBM can be modulated by copper and copper chelators. The accelerated A β aggregation in the presence of copper seems to be linked to a higher tolerance to the cytotoxic effects of this metal. Our results suggest that the formation of intracellular A β aggregates could be part of a mechanism that defends the cell against sudden changes in copper concentration.

Methods

Solutions

Distilled H₂O (dH₂O) used in buffer preparations was submitted to resin treatment in order to eliminate organic compounds, cations and anions. After treatment, the resultant dH₂O had a resistance value of 18 M Ω /cm.

Nematode propagation and strains

Transgenic strains CL2120 and CL2122 were a gift of Dr. Christopher Link and were described earlier [28]. Briefly, CL2120 expresses the A β 1-42 peptide under the control of the *unc-54* (myosin heavy chain) promoter that drives expression to the body wall muscle cells. These animals form intracellular amyloid deposits constitutively in their muscle cells [69]. CL2122 has the same vector as CL2120, minus A β 1-42, incorporated into the genome and therefore it does not form amyloid aggregates. Both strains have *mtl-2*/GFP as marker gene and therefore they express GFP in the intestinal cells. The worms were cultured on regular 35, 60 or 100 mm culture plates with NGM agar seeded with the bacterial strain OP50 [70]. The agar and the bacterial cultures were supplemented with histidine (Sigma), clioquinol (Sigma) and CuCl₂ (Sigma) at a concentration of 150 μ M. All strains were maintained at 20°C. Worm cultures were synchronized by the

hypochlorite method [71] and the resulting eggs were seeded onto the previously described agar plates. The animals were collected every 24 h by washing the plates with M9 buffer [71]. The worms were precipitated in a clinical centrifuge and the M9 removed. The nematodes were then stained as described below.

A β mutagenesis

Construction of the transgenic strains expressing the A β variants, Arctic (E22G) and NIC (V18A) (Fig. 1A), were obtained by site directed mutagenesis on the pCL12 plasmid (kindly provided by Dr. Christopher Link) that carries the human wt A β 1-42 peptide (with a signal peptide in the N-terminus) under the control of the *unc-54* promoter that drives expression to the body wall muscle cells [28]. The NIC mutation (V18A) induces a significant increment in the α -helical content of A β and dramatically diminishes fibrillogenesis *in vitro* [14]. The primers used to generate the Arctic (5'TGGTGTTCITTCAGGAGATGTGGTTCAAA3' and its complementary anti-sense primer) and NIC (5'ATCATCAAAAATTGGCGTTCITTCAGAGA3' and its complementary anti-sense primer) mutations were obtained commercially (Invitrogen). We obtained plasmids pPG110 and pPG120 carrying the Arctic and the NIC variant respectively as established by sequencing the DNA inserts. The transgenic lines were created using microparticle bombardment of the plasmid of interest and the selectable co-transformation marker *unc-119* (pJN254) into *unc-119* (*e2498*) mutants, as described earlier except that we used tungsten particles instead of gold particles [72]. The presence of each transgene was determined by PCR (primer sense 5'TGACCGTGGAAGATTA 3' located in the *unc-54* promoter and primer antisense 5'GTCCAATGATTGCACCT 3' between bases 1208 and 1224 of the pCL12 plasmid and its derivatives pPG110 and pPG120 (Fig. 1B). The expression of the transgenes was established by western blot analysis (Fig. 1C and 1D) and immunofluorescence (6E10 antibody, Sigma) (Fig. 3). We obtained 4 transgenic lines that express the NIC variant and 10 expressing the Arctic variant. For Western analysis we choose lines in which the transgene was incorporated into the genome and therefore transferred to 100% of the progeny. For the analysis of intracellular aggregation (ThS and immunofluorescence) we choose lines with equivalent A β expression (NIC2). This was not possible for the Arctic variant since it we could not obtain strains expressing this variant at high levels, but we nevertheless analysed strain Arctic 6.

Western blot analysis

Worms were collected from the plates with M9 buffer, transferred to tubes, centrifuged and washed two times to eliminate bacteria. The final worm pellet was resuspended in 100 μ l lysis buffer (50 mM HEPES pH = 7.5; 6 mM MgCl₂; 1 mM EDTA; 75 mM sucrose; 25 mM benzami-

dine; 1 mM DTT; 1% Triton X-100) and frozen at 80°C. The samples were sonicated 2 times on ice for 15 seconds and centrifuged 5 minutes at 10,000 rpm to eliminate the cuticles. The supernatant was transferred to a new tube and total protein content was quantified. Then, a volume corresponding to 50 µg protein was precipitated with acetone. The pellet was resuspended in loading buffer (50 mM Tris-HCl pH6.8; 100 mM DTT; 5% SDS; 10 % glycerol; bromophenol blue; 5% β-mercaptoethanol) and boiled for 3 minutes (adapted from Wu et al. 2006). The samples were subjected to electrophoresis on Tris-Tricine polyacrilamide gels at constant voltage (100 V) at 4°C. The proteins were then transferred to PVDF membranes for 2 hours at 4°C (300 mA). The membranes were boiled in PBS for 3 minutes before blocking with a solution of PBT plus 5% milk for one hour at room temperature. We used the anti-Aβ monoclonal antibody 6E10 (Chemicon) at 1:1,000 dilution or anti-α-tubulin monoclonal antibody (Sigma) at 1:5,000 dilution overnight at 4°C. We used goat anti-mouse HRP as secondary antibody. The densitometry analysis was performed with Matrix software.

Immunofluorescence

We used the monoclonal anti-Aβ antibody 6E10 (Sigma) and as secondary antibody an anti-mouse Alexa Fluor 488 (Molecular Probes) pre-adsorbed with fixed worms. The fixation, permeabilization, and staining of the specimens were performed as described before [73]. Some samples were also stained with rhodamine-phalloidin (1:4,000) for the visualization of actin filaments in muscle cells.

ThS fluorescence staining

ThS staining was performed as described before [28] with the modification that it was done in whole *C. elegans* populations instead of on individual worms. Briefly, the worms washed from the plates were submitted to a brief centrifugation at 3,000 rpm in microfuge tubes and fixed by adding 1 ml 4% paraformaldehyde in PBS pH 7.4 for 24 h at 4°C. The next day, the fixative was removed, replaced by 0.5 ml permeabilization solution (1% Triton X-100, 5% β-mercaptoethanol, 125 mM Tris, pH 7.4), and incubated at 37°C for 24 h. After removing the permeabilization solution the animals were washed in PBS-T (Triton X-100 0.1%) pH 7.4, stained in 0.125% ThS in 50% ethanol for 2 min and destained for another 2 min in 50% ethanol. The 50% ethanol was removed; the worm pellet was resuspended in a drop of PBS and a small aliquot observed under a Zeiss Axioplan microscope. If the background of the staining was too high a second wash with 50% ethanol was performed. The animals were finally mounted on a drop of mounting medium (DAKO), covered with a cover slip and sealed. The samples were coded, and the counting and analysis was performed double blind. The samples were then observed and photographed

with a Zeiss Axioplan microscope equipped with epifluorescence or analysed in a Zeiss LSM 2000 MT confocal microscope. To quantify the amyloid aggregates, the ThS stained deposits present anterior to the pharyngeal bulb were counted in a minimum of 40 worms in three independent experiments.

Image quantification and statistical analysis

Digital quantification of areas positive for ThS fluorescence were measured with the Sigma Scan Pro 5 or ImageJ. The analysis revealed the total average area of the deposits. The total area of deposits was divided by the total head area to standardize it to the worm size. Data from the image analysis microscopy were exported to a Sigma Plot file or GraphPad Prism 4 for statistical analysis. Results were expressed as mean ± standard error. Statistical significance was determined by one-way analysis of variance (ANOVA); $p < 0.05$ was regarded as statistically significant.

Metal Quantification

C. elegans worms were grown during 96 or 120 h on regular agar plates or agar plates supplemented with 150 µM CuCl₂. The animals were washed off the plates with dH₂O, placed on microfuge tubes and subjected to three washes with dH₂O, they were then heated 2 times at 100°C for 15 min. All samples were stored at 4°C. To avoid possible metal contaminations, the tubes used to collect the samples were previously treated with 0.5% HNO₃ for 24 h, washed with dH₂O 3 times and let dry at 20°C. The samples were digested in 200 µl of 12N HNO₃ (BDH, ARISTAR) overnight, the next day 200 µl of 1% HNO₃ were added. Samples were further diluted (1:10) in 1% HNO₃ for analysis by inductive coupled plasma mass spectrometry (ICP-MS). ICP-MS was performed using an UltraMass 700 (Varian Inc., Australia). Tissue samples were prepared in triplicate for all treatments and Cu²⁺ values for each sample was determined in triplicate. Cu²⁺ values are mean µg/g weight of each *C. elegans* sample.

Cu²⁺ toxicity assays

Age-synchronous *C. elegans* populations were prepared by transferring eggs to a freshly seeded NGM plate. After 96 h, the worms were transferred to K medium (53 mM NaCl, 32 mM KCl) supplemented with different concentrations of CuCl₂ (up to 450 µM) on 24 well microtiter plates (15–20 worms/well) for 24 h at 20°C [44]. The number of dead worms was determined by the absence of touch-provoked movement when prodded with a platinum wire. Each independent experiment of a total of three was performed in triplicate.

Lifespan assays

Lifespan analysis was conducted at 20°C as described previously [74]. For the lifespan assays, 5–10 adult animals

were allowed to lay eggs overnight on regular NGM plates seeded with OP50 bacteria. Parents were removed the next day and eggs were allowed to develop at 20°C. L4 larvae were transferred to new regular NGM plates or to 150 µM CuCl₂ supplemented plates. This time point was used as day 0 to account for differences in developmental time between strains. The worms were transferred to new plates every day during the first 4–5 days to avoid the mixing of generations. The number of dead individuals was verified every two days. A worm was considered dead when it did not respond when prodded two times with a platinum wire pick. Worms that died with larvae inside (eggs hatched before being laid) or those in which the intestine extruded from the vulva were removed from the sample. Lifespan curves were generated and analyzed with GraphPad PRISM® version 5.0. Log-rank (Mantel-Cox) test was used for statistical analysis of survival curves.

Thrashing assays

Individual animals of the same age were placed on an 80 µl drop of M9 buffer. After a 2-minute recovery period the worms were recorded for 1.5 minutes and the thrashes counted. A thrash is defined as a change in the direction of bending at the mid body [47]. For the copper treatment experiments, the worms to be assayed were exposed to copper from the embryo (egg) stage in agar plates until the thrashing experiments were performed at 72 h (1 day-old adults), and 168 h later (5 day-old adults).

Competing interests

AIB is a shareholder; consultant and Scientific Advisory Board member of Prana Biotechnology Ltd. CM is a director of Prana Biotechnology Ltd., Chairperson of its Scientific Advisory Committee and stockholder. IV and RC declare competing financial interests associated to Prana Biotechnology LTD.

Authors' contributions

ANM participated in the design and coordination of the study, carried out the Aβ aggregation experiments, the toxicity assays, and drafted the manuscript, DLR performed the behavioural studies, the quantification of amyloid deposits and the statistical analysis, PMG carried out the *in vitro* mutagenesis and constructed the transgenic strains, RF contributed with the medical aspects of the study, RA performed the lifespan experiments and analysis, IV and RAC performed the metal quantifications, CO participated in the design and coordination of the study, CM participated in the design of the study, AIB participated in the design and coordination of the study and helped draft the manuscript, NCI conceived the study, participated in its design and coordination of the manuscript. All authors read and approved the final manuscript.

Additional material

Additional file 1

Aβ transgenic C. elegans and controls have similar life spans. Survival curves of control worms and Aβ worms cultured on regular agar medium. Comparison of survival curves using the Log-rank (Mantel-Cox) test yielded a p = 0.1. Survival curves are not different.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1750-1326-4-2-S1.tiff>]

Additional file 2

Aβ transgenic C. elegans are protected from Cu²⁺ toxicity in motility assays. Representative video of thrashing assays (movement in liquid medium) performed on control worms of 168 h cultured on 150 µM copper supplemented agar.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1750-1326-4-2-S2.mov>]

Additional file 3

Aβ transgenic C. elegans are protected from Cu²⁺ toxicity in motility assays. Representative video of thrashing assays (movement in liquid medium) performed on control worms of 168 h cultured on 150 µM copper supplemented agar.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1750-1326-4-2-S3.mov>]

Acknowledgements

We thank Dr. Christopher Link (University of Colorado, Boulder, USA) for his generous gift of *C. elegans* strains and plasmid pCL12 and Dr. Jeremy Nance (New York University, New York, USA) for plasmid pJN254. We also thank Andrea S. Boccardo for technical assistance.

Some nematode strains used in this work were provided by the Caenorhabditis Genetics Center, which is funded by the NIH National Center for Research Resources (NCRR). This work was supported by the International Copper Association (ICA, New York, N.Y.), FONDAP-Bio-medicine grant N° 13980001, Millennium Institute of Fundamental and Applied Biology (MIFAB), the Center for Aging and Regeneration (CARE), PFB 12/2007, Base Financing Program for Scientific and Technological Centers of Excellence, CONICYT, the Alzheimer's Association, the NHMRC and the NIA (R01AG12686 to AIB).

References

1. Askanas V, Engel WK: **Inclusion-body myositis: a myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition.** *Neurology* 2006, **66**:S39-48.
2. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K: **Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels.** *Embo J* 1985, **4**:2757-2763.
3. Askanas V, Engel WK: **Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms.** *Curr Opin Neurol* 2002, **15**:525-531.
4. McFerrin J, Engel WK, Askanas V: **Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion-body myopathies.** *Neuroreport* 1998, **9**:3201-3205.

5. Askanas V, Engel WK: **Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis.** *Curr Opin Rheumatol* 2007, **19**:550-559.
6. Rebolledo DL, Minniti AN, Grez PM, Fadic R, Kohn R, Inestrosa NC: **Inclusion body myositis: a view from the *Caenorhabditis elegans* muscle.** *Mol Neurobiol* 2008, **38**:178-198.
7. Selkoe DJ: **Alzheimer's disease: genes, proteins, and therapy.** *Physiol Rev* 2001, **81**:741-766.
8. Hori Y, Hashimoto T, Wakutani Y, Urakami K, Nakashima K, Condrón MM, Tsubuki S, Saido TC, Teplow DB, Iwatsubo T: **The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate A β fibril formation without increasing protofibril formation.** *J Biol Chem* 2007, **282**:4916-4923.
9. Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, Lannfelt L: **Physicochemical characterization of the Alzheimer's disease-related peptides A β 1-42Arctic and A β 1-42wt.** *Febs J* 2006, **273**:2618-2630.
10. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT Jr: **Mixtures of wild-type and a pathogenic (E22G) form of A β 40 in vitro accumulate protofibrils, including amyloid pores.** *J Mol Biol* 2003, **332**:795-808.
11. Murakami K, Irie K, Morimoto A, Ohigashi H, Shindo M, Nagao M, Shimizu T, Shirasawa T: **Neurotoxicity and physicochemical properties of A β mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease.** *J Biol Chem* 2003, **278**:46179-46187.
12. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condrón MM, Axelman K, Forsell C, Sten C, Luthman J, Teplow DB, Younkin SG, et al.: **The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced A β protofibril formation.** *Nat Neurosci* 2001, **4**:887-893.
13. Cheng IH, Palop JJ, Esposito LA, Bien-Ly N, Yan F, Mucke L: **Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation.** *Nat Med* 2004, **10**:1190-1192.
14. Soto C, Castano EM, Frangione B, Inestrosa NC: **The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation.** *J Biol Chem* 1995, **270**:3063-3067.
15. Morgan C, Colombres M, Nunez MT, Inestrosa NC: **Structure and function of amyloid in Alzheimer's disease.** *Prog Neurobiol* 2004, **74**:323-349.
16. Selkoe DJ: **The cell biology of β -amyloid precursor protein and presenilin in Alzheimer's disease.** *Trends Cell Biol* 1998, **8**:447-453.
17. Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretschmar H, Sisodia S, Müller U: **Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members.** *Embo J* 2004, **23**:4106-4115.
18. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY: **Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice.** *Proc Natl Acad Sci USA* 2002, **99**:7705-7710.
19. Lee JY, Mook-Jung I, Koh JY: **Histochemically reactive zinc in plaques of the Swedish mutant β -amyloid precursor protein transgenic mice.** *J Neurosci* 1999, **19**:RC10.
20. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR: **Copper, iron and zinc in Alzheimer's disease senile plaques.** *J Neurol Sci* 1998, **158**:47-52.
21. Bush AI, Pettingell WH, Multhaup G, d Paradis M, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE: **Rapid induction of Alzheimer A β amyloid formation by zinc.** *Science* 1994, **265**:1464-1467.
22. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, et al.: **Treatment with a copper-zinc chelator markedly and rapidly inhibits β -amyloid accumulation in Alzheimer's disease transgenic mice.** *Neuron* 2001, **30**:665-676.
23. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI: **Aqueous dissolution of Alzheimer's disease A β amyloid deposits by biometal depletion.** *J Biol Chem* 1999, **274**:23223-23228.
24. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, et al.: **Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A β amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.** *Arch Neurol* 2003, **60**:1685-1691.
25. Bayer TA, Schafer S, Simons A, Kemmling A, Kamer T, Tepest R, Eckert A, Schussel K, Eikenberg O, Sturchler-Pierrat C, et al.: **Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid A β production in APP23 transgenic mice.** *Proc Natl Acad Sci USA* 2003, **100**:14187-14192.
26. Cruz L, Urbanc B, Buldyrev SV, Christie R, Gomez-Isla T, Havlin S, McNamara M, Stanley HE, Hyman BT: **Aggregation and disaggregation of senile plaques in Alzheimer disease.** *Proc Natl Acad Sci USA* 1997, **94**:7612-7616.
27. Daigle I, Li C: **apl-1, a *Caenorhabditis elegans* gene encoding a protein related to the human β -amyloid protein precursor.** *Proc Natl Acad Sci USA* 1993, **90**:12045-12049.
28. Fay DS, Fluet A, Johnson CJ, Link CD: **In vivo aggregation of β -amyloid peptide variants.** *J Neurochem* 1998, **71**:1616-1625.
29. Drake J, Link CD, Butterfield DA: **Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid β -peptide (1-42) in a transgenic *Caenorhabditis elegans* model.** *Neurobiol Aging* 2003, **24**:415-420.
30. Fonte V, Kapulkin V, Taft A, Fluet A, Friedman D, Link CD: **Interaction of intracellular β amyloid peptide with chaperone proteins.** *Proc Natl Acad Sci USA* 2002, **99**:9439-9444.
31. Link CD, Cypser JR, Johnson CJ, Johnson TE: **Direct observation of stress response in *Caenorhabditis elegans* using a reporter transgene.** *Cell Stress Chaperones* 1999, **4**:235-242.
32. Link CD, Taft A, Kapulkin V, Duke K, Kim S, Fei Q, Wood DE, Sahagan BG: **Gene expression analysis in a transgenic *Caenorhabditis elegans* Alzheimer's disease model.** *Neurobiol Aging* 2003, **24**:397-413.
33. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y: **Amyloid- β -induced pathological behaviors are suppressed by Ginkgo biloba extract EGB 761 and ginkgolides in transgenic *Caenorhabditis elegans*.** *J Neurosci* 2006, **26**:13102-13113.
34. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL: **A β oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine.** *J Biol Chem* 2007, **282**:11590-11601.
35. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL: **A β oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease.** *J Neurosci* 2007, **27**:796-807.
36. Hammans S: **Inclusion Body Myositis.** *Southampton for the Muscular Dystrophy Campaign. London* 2003 [http://www.muscular-dystrophy.org/information_resources/factsheets/medical_conditions_factsheets/inclusion_body.html].
37. Phinney AL, Drisaldi B, Schmidt SD, Lugowski S, Coronado V, Liang Y, Horne P, Yang J, Sekoulidis J, Coomaraswamy J, et al.: **In vivo reduction of amyloid- β by a mutant copper transporter.** *Proc Natl Acad Sci USA* 2003, **100**:14193-14198.
38. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI: **Dramatic aggregation of Alzheimer A β by Cu(II) is induced by conditions representing physiological acidosis.** *J Biol Chem* 1998, **273**:12817-12826.
39. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, Bush AI: **Metalloenzyme-like activity of Alzheimer's disease β -amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2).** *J Biol Chem* 2002, **277**:40302-40308.
40. Link CD, Johnson CJ: **Reporter transgenes for study of oxidant stress in *Caenorhabditis elegans*.** *Methods Enzymol* 2002, **353**:497-505.
41. Link CD, Johnson CJ, Fonte V, Paupard M, Hall DH, Styren S, Mathis CA, Klunk WE: **Visualization of fibrillar amyloid deposits in living, transgenic *Caenorhabditis elegans* animals using the sensitive amyloid dye, X-34.** *Neurobiol Aging* 2001, **22**:217-226.
42. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, Bush AI: **Characterization of copper interactions with Alzheimer amyloid β peptides: identification of an attomolar-affinity copper binding site on amyloid β 1-42.** *J Neurochem* 2000, **75**:1219-1233.

43. Stringham E, Candido E: **Transgenic Hsp 16-LacZ Strains of the Soil Nematode *Caenorhabditis elegans* as Biological Monitors of Environmental Stress.** *Environmental Toxicology and Chemistry* 1994, **13**:1211-1220.
44. Barsyte D, Lovejoy DA, Lithgow GJ: **Longevity and heavy metal resistance in *daf-2* and *age-1* long-lived mutants of *Caenorhabditis elegans*.** *Faseb J* 2001, **15**:627-634.
45. Candido EP, Jones D: **Transgenic *Caenorhabditis elegans* strains as biosensors.** *Trends Biotechnol* 1996, **14**:125-129.
46. Bush AI, Masters CL, Tanzi RE: **Copper, β -amyloid, and Alzheimer's disease: tapping a sensitive connection.** *Proc Natl Acad Sci USA* 2003, **100**:11193-11194.
47. Miller KG, Alfonso A, Nguyen M, Crowell JA, Johnson CD, Rand JB: **A genetic selection for *Caenorhabditis elegans* synaptic transmission mutants.** *Proc Natl Acad Sci USA* 1996, **93**:12593-12598.
48. Ackley BD, Kang SH, Crew JR, Suh C, Jin Y, Kramer JM: **The basement membrane components nidogen and type XVIII collagen regulate organization of neuromuscular junctions in *Caenorhabditis elegans*.** *J Neurosci* 2003, **23**:3577-3587.
49. Doi M, Iwasaki K: **Regulation of retrograde signaling at neuromuscular junctions by the novel C2 domain protein AEX-1.** *Neuron* 2002, **33**:249-259.
50. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puolivalli J, Lesne S, Ashe KH, Muchowski PJ, Mucke L: **Accelerating amyloid- β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models.** *J Biol Chem* 2007, **282**:23818-23828.
51. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, Metherate R, Mattson MP, Akbari Y, LaFerla FM: **Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction.** *Neuron* 2003, **39**:409-421.
52. Aldridge S: **News. In brief: New Alzheimer's endpoints?** *Nat Biotechnol* 2008, **26**:482.
53. Jin Y: *C. elegans: A practical approach* Oxford: Oxford University Press; 1999.
54. Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, Honda K, Smith MA, Perry G: **Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease.** *Neurobiol Dis* 2004, **17**:108-113.
55. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, et al.: **Oxidative damage is the earliest event in Alzheimer disease.** *J Neuropathol Exp Neurol* 2001, **60**:759-767.
56. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA: **Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome.** *Ann N Y Acad Sci* 1999, **893**:362-364.
57. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA: **Neuronal oxidative stress precedes amyloid- β deposition in Down syndrome.** *J Neuropathol Exp Neurol* 2000, **59**:1011-1017.
58. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI: **Metal chelation as a potential therapy for Alzheimer's disease.** *Ann N Y Acad Sci* 2000, **920**:292-304.
59. Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G, Nakamura M: **Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid- β peptide.** *Free Radic Biol Med* 2007, **43**:1552-1559.
60. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV: **Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase.** *Science* 1999, **284**:805-808.
61. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX: **Metals and amyloid- β in Alzheimer's disease.** *Int J Exp Pathol* 2005, **86**:147-159.
62. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX: **Overexpression of Alzheimer's disease amyloid- β opposes the age-dependent elevations of brain copper and iron.** *J Biol Chem* 2002, **277**:44670-44676.
63. Owen CA Jr: **Uptake of ^{67}Cu by ceruloplasmin in vitro.** *Proc Soc Exp Biol Med* 1975, **149**:681-682.
64. Yates CM, Butterworth J, Tennant MC, Gordon A: **Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias.** *J Neurochem* 1990, **55**:1624-1630.
65. Cerpa W, Varela-Nallar L, Reyes AE, Minniti AN, Inestrosa NC: **Is there a role for copper in neurodegenerative diseases?** *Mol Aspects Med* 2005, **26**:405-420.
66. Cerpa WF, Barria MI, Chacon MA, Suazo M, Gonzalez M, Opazo C, Bush AI, Inestrosa NC: **The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu $^{2+}$ neurotoxicity in vivo.** *Faseb J* 2004, **18**:1701-1703.
67. Zou K, Gong JS, Yanagisawa K, Michikawa M: **A novel function of monomeric amyloid β -protein serving as an antioxidant molecule against metal-induced oxidative damage.** *J Neurosci* 2002, **22**:4833-4841.
68. Sparks DL, Schreurs BG: **Trace amounts of copper in water induce β -amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease.** *Proc Natl Acad Sci USA* 2003, **100**:11065-11069.
69. Link CD: **Expression of human β -amyloid peptide in transgenic *Caenorhabditis elegans*.** *Proc Natl Acad Sci USA* 1995, **92**:9368-9372.
70. Brenner S: **The genetics of *Caenorhabditis elegans*.** *Genetics* 1974, **77**:71-94.
71. Lewis JA, Fleming JT: **Basic culture methods.** *Methods Cell Biol* 1995, **48**:3-29.
72. Praitis V, Casey E, Collar D, Austin J: **Creation of low-copy integrated transgenic lines in *Caenorhabditis elegans*.** *Genetics* 2001, **157**:1217-1226.
73. Finney M, Ruvkun G: **The *unc-86* gene product couples cell lineage and cell identity in *C. elegans*.** *Cell* 1990, **63**:895-905.
74. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R: **A *C. elegans* mutant that lives twice as long as wild type.** *Nature* 1993, **366**:461-464.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

